BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

About BDSI

Meet BDSI

A company dedicated to driving innovative solutions for the treatment of serious and debilitating chronic conditions.

Everyone deserves to live life to their fullest potential.

BDSI works to advance therapies designed to give individuals living with serious and debilitating chronic conditions the opportunity to make the most of their lives.

Discover the BDSI portfolio of products
About BDSI
About BDSI

Being a leader means driving meaningful change.

BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company committed to finding therapies for serious and debilitating chronic conditions and bringing them to market in the most impactful way possible.

Find out how you can grow with us

We focus on the patient, not just the condition.

In our relentless pursuit of innovative therapies, tools, and technologies, we never lose sight of the human element.

Learn more about our patients-first philosophy
About BDSI
About BDSI

Passion is part of our job description.

As a patient-centric pharmaceutical company, we are passionate about lifting the burden of serious and debilitating chronic conditions.

Find out how you can put your passion to work

Be a voice for your patients.

Serious and debilitating chronic conditions are complex and often misunderstood, which can leave patients feeling isolated and alone. At BDSI, we believe reaching out and advocating for our patient communities is an important part of driving therapeutic solutions.

Connect with some of our advocacy efforts
About BDSI
About BDSI

A forward-focused mission.

With every new product, our mission expands to embrace a new patient population, their caregivers, and family.

Learn how our products may help
About BDSI

Everyone deserves to live life to their fullest potential.

BDSI works to advance therapies designed to give individuals living with serious and debilitating chronic conditions the opportunity to make the most of their lives.

Discover the BDSI portfolio of products
About BDSI

Being a leader means driving meaningful change.

BioDelivery Sciences International (BDSI) is a rapidly growing specialty pharmaceutical company committed to finding therapies for serious and debilitating chronic conditions and bringing them to market in the most impactful way possible.

Find out how you can grow with us
About BDSI

We focus on the patient, not just the condition.

In our relentless pursuit of innovative therapies, tools, and technologies, we never lose sight of the human element.

Learn more about our patients-first philosophy
About BDSI

Passion is part of our job description.

As a patient-centric pharmaceutical company, we are passionate about lifting the burden of serious and debilitating chronic conditions.

Find out how you can put your passion to work
About BDSI

Be a voice for your patients.

Serious and debilitating chronic conditions are complex and often misunderstood, which can leave patients feeling isolated and alone. At BDSI, we believe reaching out and advocating for our patient communities is an important part of driving therapeutic solutions.

Connect with some of our advocacy efforts
About BDSI

A forward-focused mission.

With every new product, our mission expands to embrace a new patient population, their caregivers, and family.

Learn how our products may help

Recent BDSI News

May 29, 2020

RALEIGH, N.C. , May 29, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Interim Chief Executive

Read more
May 11, 2020

RALEIGH, N.C. , May 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey A.

Read more
May 7, 2020

First Quarter Total Company Net Sales Increased 94% versus Prior Year to $38.3 Million First Quarter BELBUCA® Net Sales Increased 79% versus Prior Year to $33.5 Million Conference Call and Webcast Scheduled for 4:30 PM EST Today RALEIGH, N.C. , May 07, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences

Read more
More news

Upcoming Events

William Blair 40th Annual Growth Stock Conference June 11, 2020 9:40 AM EDT
Jefferies Virtual Healthcare Conference June 2, 2020 3:00 PM EDT

Stay Connected

Stay up to date on the latest news

Get started now
May 29, 2020BDSI $4.78/ - -0.21%
Data provided by Nasdaq. Minimum 15 minutes delayed.